Clinical Trial Update: MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for MB-CART19.1 in CD19+ B-cell malignancies sponsored by Miltenyi Biomedicine GmbH. The study includes recurrent or refractory ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• MB-CART19.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent | Phase 1 | Status: ACTIVE_NOT_RECRUITING